BMF‐219 is in Phase 1 trial for AML and ALL with a translocated KMT2A gene or NPM1 mutations, DLBCL, MM, CLL and SLL patients, NCT05153330;. This evidence concerns the gene NPM1 and Miyoshi myopathy.